[go: up one dir, main page]

WO2008105383A1 - ピラゾール誘導体およびその医薬用途 - Google Patents

ピラゾール誘導体およびその医薬用途 Download PDF

Info

Publication number
WO2008105383A1
WO2008105383A1 PCT/JP2008/053230 JP2008053230W WO2008105383A1 WO 2008105383 A1 WO2008105383 A1 WO 2008105383A1 JP 2008053230 W JP2008053230 W JP 2008053230W WO 2008105383 A1 WO2008105383 A1 WO 2008105383A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazole derivative
medical purposes
disclosed
pyrazole
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053230
Other languages
English (en)
French (fr)
Inventor
Yuji Sugawara
Hideyuki Tsutsui
Yasuhiro Morita
Naoki Izumimoto
Mika Morimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of WO2008105383A1 publication Critical patent/WO2008105383A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　本発明は、下記式 [化１] で代表されるピラゾール誘導体およびその医薬用途に関する。本発明のピラゾール誘導体は、鎮痛薬または神経因性疼痛治療または予防薬として有効である。
PCT/JP2008/053230 2007-02-26 2008-02-26 ピラゾール誘導体およびその医薬用途 Ceased WO2008105383A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007045678 2007-02-26
JP2007-045678 2007-02-26

Publications (1)

Publication Number Publication Date
WO2008105383A1 true WO2008105383A1 (ja) 2008-09-04

Family

ID=39721215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053230 Ceased WO2008105383A1 (ja) 2007-02-26 2008-02-26 ピラゾール誘導体およびその医薬用途

Country Status (1)

Country Link
WO (1) WO2008105383A1 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010050577A1 (ja) 2008-10-31 2010-05-06 東レ株式会社 シクロヘキサン誘導体及びその医薬用途
WO2011125836A1 (ja) 2010-03-31 2011-10-13 東レ株式会社 線維筋痛症の治療剤又は予防剤
WO2011125838A1 (ja) 2010-03-31 2011-10-13 東レ株式会社 蓄尿障害の治療剤又は予防剤
WO2011136318A1 (ja) 2010-04-28 2011-11-03 東レ株式会社 アルツハイマー病の治療剤又は予防剤
JP2014172851A (ja) * 2013-03-07 2014-09-22 Chiba Univ ピラゾール誘導体の製造方法およびイソオキサゾール誘導体の製造方法
WO2015115509A1 (ja) 2014-01-29 2015-08-06 東レ株式会社 多発性硬化症の治療剤又は予防剤
CN106674084A (zh) * 2016-12-20 2017-05-17 山东轩德医药科技有限公司 一种2‑异丙基氧基‑5‑甲基‑4‑(哌啶‑4‑基)苯胺二盐酸盐的制备方法
US9951025B2 (en) 2013-03-15 2018-04-24 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
US9963440B2 (en) 2010-03-30 2018-05-08 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US10058541B2 (en) 2013-03-15 2018-08-28 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
CN108863803A (zh) * 2018-06-15 2018-11-23 上海华堇生物技术有限责任公司 一种4-甲氧基-β-硝基苯乙烯的新制备方法
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038418A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JP2006514095A (ja) * 2002-12-02 2006-04-27 アステラス製薬株式会社 ピラゾール誘導体
WO2007111323A1 (ja) * 2006-03-27 2007-10-04 Toray Industries, Inc. ウレイド誘導体およびその医薬用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038418A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JP2006514095A (ja) * 2002-12-02 2006-04-27 アステラス製薬株式会社 ピラゾール誘導体
WO2007111323A1 (ja) * 2006-03-27 2007-10-04 Toray Industries, Inc. ウレイド誘導体およびその医薬用途

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349874B2 (en) 2008-10-31 2013-01-08 Toray Industries, Inc. Cyclohexane derivative and pharmaceutical use thereof
WO2010050577A1 (ja) 2008-10-31 2010-05-06 東レ株式会社 シクロヘキサン誘導体及びその医薬用途
US8247569B2 (en) 2008-10-31 2012-08-21 Toray Industries, Inc. Cyclohexane derivative and pharmaceutical use thereof
JP5522031B2 (ja) * 2008-10-31 2014-06-18 東レ株式会社 シクロヘキサン誘導体及びその医薬用途
US10653674B2 (en) 2010-03-30 2020-05-19 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US9963440B2 (en) 2010-03-30 2018-05-08 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US8957094B2 (en) 2010-03-31 2015-02-17 Toray Industries, Inc. Therapeutic agent or prophylactic agent for fibromyalgia
KR101738471B1 (ko) 2010-03-31 2017-05-22 도레이 카부시키가이샤 섬유근 통증의 치료제 또는 예방제
EP2554541A4 (en) * 2010-03-31 2013-10-09 Toray Industries THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA
WO2011125836A1 (ja) 2010-03-31 2011-10-13 東レ株式会社 線維筋痛症の治療剤又は予防剤
US8642625B2 (en) 2010-03-31 2014-02-04 Toray Industries, Inc. Therapeutic agent or preventive agent for urine collection disorder
CN102812008A (zh) * 2010-03-31 2012-12-05 东丽株式会社 蓄尿障碍的治疗剂或预防剂
WO2011125838A1 (ja) 2010-03-31 2011-10-13 東レ株式会社 蓄尿障害の治療剤又は予防剤
CN102812008B (zh) * 2010-03-31 2015-01-07 东丽株式会社 蓄尿障碍的治疗剂或预防剂
KR101739879B1 (ko) 2010-03-31 2017-05-25 도레이 카부시키가이샤 축뇨장해의 치료제 또는 예방제
CN102822148A (zh) * 2010-03-31 2012-12-12 东丽株式会社 纤维肌痛综合征的治疗剂或预防剂
JP5783042B2 (ja) * 2010-03-31 2015-09-24 東レ株式会社 蓄尿障害の治療剤又は予防剤
KR101739881B1 (ko) 2010-04-28 2017-05-25 도레이 카부시키가이샤 알츠하이머병의 치료제 또는 예방제
US8598212B2 (en) 2010-04-28 2013-12-03 Toray Industries, Inc. Therapeutic agent and preventative agent for alzheimer's disease
JP5682555B2 (ja) * 2010-04-28 2015-03-11 東レ株式会社 アルツハイマー病の治療剤又は予防剤
WO2011136318A1 (ja) 2010-04-28 2011-11-03 東レ株式会社 アルツハイマー病の治療剤又は予防剤
JP2014172851A (ja) * 2013-03-07 2014-09-22 Chiba Univ ピラゾール誘導体の製造方法およびイソオキサゾール誘導体の製造方法
US9951025B2 (en) 2013-03-15 2018-04-24 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
US10058541B2 (en) 2013-03-15 2018-08-28 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
US10251872B2 (en) 2013-03-15 2019-04-09 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
WO2015115509A1 (ja) 2014-01-29 2015-08-06 東レ株式会社 多発性硬化症の治療剤又は予防剤
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CN106674084B (zh) * 2016-12-20 2019-03-01 山东轩德医药科技有限公司 一种2-异丙基氧基-5-甲基-4-(哌啶-4-基)苯胺二盐酸盐的制备方法
CN106674084A (zh) * 2016-12-20 2017-05-17 山东轩德医药科技有限公司 一种2‑异丙基氧基‑5‑甲基‑4‑(哌啶‑4‑基)苯胺二盐酸盐的制备方法
CN108863803A (zh) * 2018-06-15 2018-11-23 上海华堇生物技术有限责任公司 一种4-甲氧基-β-硝基苯乙烯的新制备方法

Similar Documents

Publication Publication Date Title
WO2008105383A1 (ja) ピラゾール誘導体およびその医薬用途
GEP20166443B (en) Heterocyclic compound and use thereof
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
WO2007135527A3 (en) Benzimidazolyl compounds
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008135826A3 (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
MX2010004435A (es) Compuestos espiro y uso farmaceutico de los mismos.
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2009067856A8 (zh) 组蛋白去乙酰化酶抑制剂及其制备和用途
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
PH12012501552A1 (en) Therapeutic or prophylactic agent for biliary diseases
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2009032843A3 (en) Deuterated ethambutols and their use
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
AU2005313582A8 (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711959

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711959

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP